Photo: ca.finance.yahoo.com
Lilly, Novo Nordisk Set to Finalize Obesity Drug Deals with White House
Eli Lilly and Company and Novo Nordisk are set to finalize drug pricing deals with the White House for their obesity treatments, ensuring Medicare coverage at a reduced cost.
- Eli Lilly and Company and Novo Nordisk will offer their obesity drugs at a monthly price of $149 as part of a deal with the White House.
- The agreement aims to secure Medicare (United States) coverage for weight loss medications, potentially announced this week, according to Endpoints News.
- Currently, U.S. patients face high costs for obesity treatments, making this arrangement with the White House significant for patient access and affordability.
Why It Matters
This deal signifies a critical step in making obesity treatments more affordable and accessible for patients under Medicare (United States), reflecting ongoing efforts to address rising healthcare costs in the U.S. It also highlights the collaboration between pharmaceutical companies like Eli Lilly and Company, Novo Nordisk, and government entities.